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ABSTRACT
Non-coding RNA regulatory elements are important
for viral replication, making them promising tar-
gets for therapeutic intervention. However, regula-
tory RNA is challenging to detect and characterise
using classical structure-function assays. Here, we
present in cell Mutational Interference Mapping Ex-
periment (in cell MIME) as a way to define RNA regula-
tory landscapes at single nucleotide resolution under
native conditions. In cell MIME is based on (i) random
mutation of an RNA target, (ii) expression of mutated
RNA in cells, (iii) physical separation of RNA into
functional and non-functional populations, and (iv)
high-throughput sequencing to identify mutations af-
fecting function. We used in cell MIME to define RNA
elements within the 5′ region of the HIV-1 genomic
RNA (gRNA) that are important for viral replication
in cells. We identified three distinct RNA motifs con-
trolling intracellular gRNA production, and two dis-
tinct motifs required for gRNA packaging into virions.
Our analysis reveals the 73AAUAAA78 polyadenyla-
tion motif within the 5′ PolyA domain as a dual regu-
lator of gRNA production and gRNA packaging, and
demonstrates that a functional polyadenylation sig-
nal is required for viral packaging even though it neg-
atively affects gRNA production.
INTRODUCTION
Once thought to be a passive carrier of genetic information
between the DNA and the protein world, RNA is now ap-
preciated to play a central role in the regulation of almost
all cellular activity (1). RNA is unique in that it encodes
information in both its sequence and its structure. Like its
counterpart DNA, the order of nucleotides in RNA repre-
sents the sequence of amino acids during protein synthesis.
However, unlike the regular double stranded DNA helix,
RNA molecules can fold into complex and elaborate three-
dimensional structures that impart functionality by serving
as recognition sites for proteins, small molecules, and other
nucleic acids.
RNA viruses, with their compact and efficiently encoded
genomes, are perfectmodels of complexRNA function. The
genomic RNA (gRNA) of HIV-1 encodes nine proteins:
the major structural proteins, Gag, Pol and Env; the reg-
ulatory proteins Tat and Rev; and the accessory proteins
Vpu, Vpr, Vif and Nef. In addition to its coding capacity,
the HIV-1 gRNA is replete with cis-acting regulatory se-
quences that interact in complex ways to modulate gene ex-
pression through effects on RNA processing, stability, ex-
port and translation. These regulatory sequences are espe-
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cially concentrated within the 5′ untranslated region (UTR)
and the beginning of the Gag coding sequence (2–7). This
region of the gRNA is highly structured, and folds into a
series of relatively independent functional domains (Figure
1A): the Trans-Activating Response (TAR) for transcrip-
tion; PolyA for polyadenylation; the primer binding site
(PBS) for reverse transcription; SL1 or the dimerization ini-
tiation site (DIS) for gRNA dimerization; SL2 contains the
major splice donor (SD) site; and SL3 is historically consid-
ered the major packaging signal (Psi). Together, these func-
tional domains regulate key steps of the HIV-1 life cycle (8–
11), and serve to highlight the fact that the gRNA sustains
not only protein synthesis, but is an active participant in the
viral infection process.
Because regulatory elements are essential for viral repli-
cation, they represent promising, yet still underexplored an-
tiviral targets (12). Indeed, pioneering work in Hepatitis
C virus (HCV) demonstrates that non-coding RNA can
be targeted therapeutically with high barriers to resistance,
providing impetus for the systematic discovery of functional
RNAmotifs in viral genomes (13). To date, regulatoryRNA
is most often identified using truncation or deletion mu-
tants in individual assays to define regions of functional-
ity. However, regulatory regions often overlap in complex
RNAs, making these laborious experiments difficult to in-
terpret. Indeed, attempts to define theminimal HIV-1 pack-
aging signal have led to largely conflicting results, and evi-
dence can be found in the literature that almost all regions of
the 5′UTR are required for packaging (14), including TAR
(15,16), the poly-A stem loop (17,18), PBS (14,18), SL1
(14,19–21), SL2 (22), SL3 (23–25), as well as the first nu-
cleotides of gag (6,26,27). Many of these studies used large
and imprecise deletions that likely compromised the global
folding of the RNA, and some of these studies may not be
correctly interpreted. For example, TAR was once consid-
ered part of the HIV-1 packaging signal, until work by the
Berkhout lab revealed that packaging defects were caused
by TAR mutation induced misfolding of the HIV-1 leader
RNA (28–30). Finally, truncation and deletion mutagenesis
experiments are rarely able to define regions of functionality
at single nucleotide resolution, nor do they provide enough
information to mechanistically understand RNA function.
Thus, there is an urgent need for new high-resolution and
quantitative methods to analyse RNA function, especially
within the native cellular environment.
We have recently developed Mutational Interference
Mapping Experiment (MIME) as a powerful and high res-
olution method to identify functional regions within long
RNA molecules in vitro (31). We previously used MIME to
precisely map the binding site of the HIV-1 Pr55Gag protein
on the viral gRNA in vitro, finding that Pr55Gag recognises
the region encompassing nucleotides 227 to 337 (31).Whilst
Pr55Gag binding to the gRNA is presumed to be the major
determinant of gRNA packaging into viral particles, it is
currently unclear whether Pr55Gag recognises this same site
within cells (32), nor whether there are additional regula-
tory or packaging signals that may define binding sites for
cellular (33) and viral proteins, or even nucleic acids (34).
Additionally, the minimal signal required to direct HIV-
1 gRNA into viral particles has yet to be precisely deter-
mined, with the packaging signal possibly comprising the
entire 5′UTR and up to half of the Gag coding sequence
(35,36). How such an extended packaging signal intercon-
nects with other regulatory motifs situated in the same re-
gion is an open question, whose answer would undoubtedly
help with the engineering of safeHIV-1 lentiviral vectors for
gene therapy purposes.
Here, we have adapted MIME to identify RNA regula-
tory sequences within the HIV-1 genome during its repli-
cation in cells (in cell MIME) (Figure 1B). By varying the
functional selection criteria, we obtained two distinct and
high-resolution maps of regulatory RNA controlling intra-
cellular gRNA production and gRNA packaging, respec-
tively. We found three RNA motifs regulating intracellular
gRNA production and twomotifs regulating genome pack-
aging. Strikingly, a 73AAUAAA78 hexamer sequence within
5′ PolyA regulated both gRNA production and packaging,
revealing the cellular polyadenylation machinery as a dual
regulator of HIV-1 replication.
MATERIALS AND METHODS
Molecular clones
Mutant libraries were cloned into pDRNL43 NotI AT-
Gaag Tat(–)Env which is a derivative of pDRNL43Env
(37) modified to contain (i) NotI 431GCgGCcGC439 and
NgoMIV 958GccGgC964 restriction sites for the cloning
of the mutant library (positions based on pNL43 provi-
ral DNA), (ii) a substitution in the initiation codon of
gag to prevent Gag expression (27), (iii) a stop codon
preventing Tat protein expression, (iv) a deletion in env
(for biosafety). Gag and GagPol, and accessory proteins
Tat and Rev, were expressed from the packaging vector
pCMVR8.9 (38). PolyA and SL2 mutants were intro-
duced into pDRNL43Env. Site directed mutagenesis was
carried out utilising standard molecular biology techniques
using the oligonucleotides listed in SupplementaryTable S1.
Cell culture
Human embryonic kidney 293 (HEK293T) cells weremain-
tained at 37◦C in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with glutamine, penicillin, strepto-
mycin and 10% (v/v) heat-inactivated fetal calf serum.
In cell mutational interference mapping experiment (MIME)
Mutagenesis. RNA expression vector (pDRNL43 NotI
ATGaag NgoMIV Tat(–) Env) was mutated by error-
prone PCR using the Mutazyme II DNA polymerase (Ag-
ilent) and the primers NL43 NotI Fw and NgoMIV Rv
(Supplementary Table S1). We chose Mutazyme II as it is
reported to produce a more uniform mutational spectrum
than traditional error-prone PCR. The PCR reaction vol-
ume was 50 l and consisted of 100 ng of template DNA,
1× buffer, 200 M dNTPs, 0.5 M of each primer, 2.5 U
of Mutazyme II DNA polymerase. PCR cycling conditions
were 95◦C for 2 min followed by 35 cycles of 95◦C for 30 s,
55◦C for 30 s and 72◦C for 1min.We performed two or three
rounds of PCRmutagenesis in duplicate.Mutated amplicon
libraries were further amplified with the same primers used
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Figure 1. (A) The HIV-1 5′UTR folds into a series of structural domains that control key steps of the HIV-1 life cycle including transcription, translation,
export, packaging and reverse transcription. From 5′ to 3′ these structural domains are: transactivation response (TAR) for transcription; PolyA stem loop
for polyadenylation; the primer binding site (PBS) for reverse transcription; SL1 promotes gRNA dimerization; SL2 contains the major splice donor (SD)
site; SL3 has historically been considered the major packaging signal (Psi); the sequences surrounding the AUG start codon are thought to be involved in
a base-pairing interaction with the upstream U5 region. (B) In cell Mutational Interference Mapping Experiment (in cell MIME). The proviral genome
is randomly mutated using error prone PCR, and subsequently cloned into a gRNA expression vector. The structural and enzymatic proteins, Gag and
Gag-Pol are expressed from a separate expression plasmid. Co-transfection of the mutant library and Gag/Gag-Pol expression plasmid into 293T cells
leads to the transcription of mutant RNAs and subsequent sorting of functional and non-functional RNA populations by the viral and cellular machinery.
Viral RNA present in cells and virus is reverse transcribed. Viral cDNA and the input DNA plasmid is amplified, fragmented, barcoded, sequenced on an
Illumina HiSeq2500, and analysed using the MIMEAnTo software.
for mutagenesis using Phusion polymerase (NEB). PCR re-
action volume was 50 l and consisted of ∼50 ng of mu-
tated DNA, 1×HF buffer, 200 MdNTPs, 0.5 Mof each
primer, 1 U of Phusion polymerase. Eight PCR amplifi-
cations were performed using the PCR cycling conditions
98◦C for 30 s, followed by 30 cycles of 98◦C for 10 s and
72◦C for 1 min. Amplified libraries were column purified
(Macherey-Nagel) and stored at –20◦C until further use.
Cloning of library. Column purified amplicon libraries
and the RNA expression vector pDRNL43 NotI NgoMIV
Tat(–) Env were digested with NotI and NgoMIV. Vector
and inserts were gel purified on a 1% agarose gel, and lig-
ated overnight at an approximate molar ratio of 1 (vector):5
(insert) using a temperature cycling protocol of 30 s at 10◦C
followed by 30 s at 30◦C. Overnight ligations were column
purified using Nucleospin Gel and PCR Clean-up columns
(Macherey-Nagel) and stored at –20◦C until further use.
Transfection. Transfections of HEK 293T cells were car-
ried out using the X-tremeGENE-9 DNA Transfection
Reagent (Roche) according to the manufacturer’s instruc-
tions. Briefly, cells were seeded at 70% confluence in 100mm
cell culture dishes and co-transfected with 2.5 g mutant
library, 2.5 g of pCMVR8.9 packaging vector, 1g of
pCMVRFPwith 1 l of X-tremeGENE-9 per g DNA. 36
h post-transfection, virus containing media was harvested
for storage at 4◦C and cells were replenished with fresh me-
dia to allow for a second virus harvest 24 h later. Virus con-
taining supernatant was pooled and clarified by centrifuga-
tion at 1462 g for 30 min, then passed through a 0.22 m
filter to remove cellular debris. Purified virus was concen-
trated by ultracentrifugation at 100 000 g through a 20%
sucrose cushion.
RNA extraction. RNAwas extracted from viral or cellular
pellets using TriReagent (MRC) according to the manufac-
turer’s instructions. Briefly, cells or virions were lysed in 1
ml of TriReagent and incubated at room temperature for 5
min. 0.2 ml of chloroform was added, followed by vigor-
ous mixing, and a further incubation at room temperature
for 15 min. After centrifugation at 12 000 g for 15 min at
4◦C, the upper aqueous phase was transferred into a new
tube. RNAwas precipitated by the addition of 0.5 ml of iso-
propanol and 1 g of glycogen followed by centrifugation
at 12 000 g for 15min at 4◦C.RNApellets were washed once
in 500 l of 70% EtOH, air dried, and resuspended in 200
l of RNase free H2O. Viral and cellular RNA was then
treated to remove contaminating plasmid DNA with 5 l
of RNase free DNase I (Roche), 5 l RNasin (Promega) in
1× buffer (40 mM Tris–HCl, 10 mM NaCl, 6 mM MgCl2,
1 mM CaCl2, pH 7.9) for 2 h at 37◦C. RNA was then ex-
tracted with phenol–chloroform, chloroform and precipi-
tated with EtOH, washed with 70% EtOH and dissolved in
ultra-pure water. Cellular and viral RNA pellets were dis-
solved in 200 l and 20 l of RNase free H2O, respectively.
Reverse transcription. Four microliter of RNA was mixed
with 1 l of a 10 M stock of primer NL43 544 Rv (Sup-
plementary Table S1), denatured at 90◦C for 2 min and then
chilled on ice. Reverse transcription was carried out in a
total volume of 10 l by adding 1× buffer (50 mM Tris–
HCl pH 8.3, 6 mM MgCl2, 40 mM KCl), 200 nM dNTPs
and 2 U of RNasin (Promega) and 2 U of AMV RT (MP
Biomedicals). Samples were incubated for 5 min at 42◦C,
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30 min at 50◦C and 10 min at 60◦C and diluted 1/10 with
90 l H2O before use. Negative reverse transcription con-
trols were carried out in the absence of AMV RT to check
for the absence of contaminating plasmid DNA. cDNA
was quantified by qPCR using primers NL43 C1 seq and
NL43 NgoMIV seq (Supplementary Table S1) and Bril-
liant II SYBR master mix (Agilent). cDNA was nor-
malized and amplified with primers NL43 C1 seq and
NL43 NgoMIV Seq (Supplementary Table S1) using Phu-
sion polymerase. PCR reaction volume was 50 l and con-
sisted of 105 copies of DNA, 1×HFbuffer, 200MdNTPs,
0.5 M of each primer, 1 U of Phusion polymerase. PCR
amplifications were performed in duplicate using the PCR
cycling conditions 98◦C for 10 s, followed by 30 cycles of
98◦C for 10 s, 55◦C for 15 s and 72◦C for 1 min. Pooled
PCR products were isolated on a 1% agarose gel and pu-
rified using Nucleospin Gel and PCR Clean-up columns
(Macherey-Nagel).
Fragmentation. As 2 × 100 nt Illumina sequencing does
not completely cover the∼500 bp fragment analysed in this
study, we randomly fragmented 500 ng of gel purified ds-
DNA with 2.5 l 10× buffer, 2.5 l of 10× BSA and 2.5
l of NEBNext dsDNA fragmentase in a total volume of
25 l for 45 min at 37◦C. Samples were verified on a 1%
agarose gel, and digestion was confirmed as a smear on the
gel. Fragmented samples were purified using Nucleospin
Gel and PCR Clean-up columns, according to the manu-
facturer’s instructions (Macherey-Nagel).
Library preparation. Fragmented DNA was first repaired
using 1× T4 DNA ligase buffer (NEB), 0.4 mM each
dNTPs, 1 mM ATP, 0.5 l of Escherichia coli DNA lig-
ase (from NEB NEBNext dsDNA fragmentase kit), 4.5 U
of T4 DNA polymerase (NEB) and 25 U of T4 polynu-
cleotide kinase (NEB) in 50 l total volume for 1 h at 20◦C.
Enzymes were then heat inactivated by incubating samples
for 30 min at 75◦C. DNA was A-tailed by adding 12.5 U
of Klenow fragment (3′-5′ Exo-) and 1.25 l of 100 M
dATP and incubating for 45 min at 37◦C. Following a sec-
ond round of enzyme heat inactivation for 30 min at 75◦C,
adaptor ligation was performed by adding 9 l of fresh 10×
T4DNA ligase buffer (NEB), 28l of 24%PEG600 (NEB),
1 l of 12.5 M pre-annealed adaptors, and 2.5 l of T4
DNA ligase (NEB) followed by incubation at 20◦C for 1 h.
Adaptor sequences IlluminaMAs and IlluminaMAa (Sup-
plementary Table S1) were annealed by mixing in 1× lig-
ase buffer (NEB), heating to 95◦C for 1 min and slow cool-
ing to room temperature. Samples were purified using Nu-
cleospin Gel and PCR Clean-up columns. Y-shaped Illu-
mina adaptors were converted into dsDNA using the PCR
cycling conditions 98◦C for 30 s followed by 5 cycles of
98◦C for 15 s, 63◦C for 30 s and 72◦C for 30 s using the
Illumina 1.0 and Illumina Index (Supplementary Table S1)
with Phusion polymerase. PCR reaction volume was 50 l
and consisted of adaptor ligated DNA, 1× HF buffer, 200
M dNTPs, 0.5 M of each primer, 1 U of Phusion poly-
merase. Samples were then run on a 1% agarose gel and the
range corresponding to 200–600 bp range was isolated, and
purified using Nucleospin Gel and PCRClean-up columns.
DNA libraries were quantified by qPCR using Illumina PE
PCR primer 1.0 and one of the Illumina Index primers (for
multiplexing) with Brilliant II SYBR master mix. Samples
were normalized and then re-amplified by PCR Illumina PE
PCR primer 1.0 and one of the Illumina Index primers us-
ing the PCR cycling conditions 98◦C for 30 s; followed by
6 cycles of 98◦C for 15 s, 63◦C for 30 s and 72◦C for 30 s
with Phusion polymerase. Samples were then pooled, and
a final size selection was performed on a 1% agarose gel to
re-isolate the range 200–600 bp ensuring the removal of Il-
lumina adaptor dimers. Samples were sequenced on a single
lane of a HiSeq 2500 instrument in 100 bp paired endmode,
according to established procedures (IGBMC sequencing
platform, Strasbourg, France).
RT-qPCR
Packaging efficiency of wild-type and mutant HIV-1 were
carried out by transfecting 106 293T cells with 250 ng of
plasmid using 4.5 l of polyethylenimine per g of DNA
(1 mg/ml; Polysciences). Thirty six hours post-transfection,
viral supernatant was clarified by centrifugation, syringe
filtered through 0.22 m pores, and pelleted through a
20% sucrose cushion, as outlined above. 293T cells were
washed once in PBS. Viral and cellular RNA was then ex-
tracted using TriReagent (MRC), treated with DNase I,
phenol/chloroform extracted, chloroform extracted, and
EtOH precipitated as outlined above. Cellular and viral
RNA pellets were dissolved in 200 l and 20 l of RNase
free H2O, respectively. Three microliters of RNA were
mixed with 2 l of a 5× mix of random hexamer and an-
chored oligodT (5× mix; 12.5 M dT20VN; 17.5 M N6)
denatured at 90◦C for 2 min and then chilled on ice. Re-
verse transcription was carried out in a total volume of 10
l by adding 1× buffer (50 mM Tris–HCl pH 8.3, 6 mM
MgCl2, 40 mM KCl), 200 nM dNTPs and 2 U of RNasin
and 2 U of AMV RT (MP Biomedicals). Samples were in-
cubated for 5 min at 42◦C, 30 min at 50◦C and 10 min at
60◦C and diluted 1/10 with 90 l H2O before use. Nega-
tive reverse transcription controls were carried out in the ab-
sence of AMV RT to check for the absence of contaminat-
ing plasmidDNA. gRNA, spliced viral RNA, andGAPDH
mRNA were quantified by TaqMan qPCR assay using the
primers listed in Supplementary Table S1. A standard curve
was generated from 109 to 103 copies of plasmid contain-
ing the relevant target. Negative controls demonstrated the
DNA contamination levels were present at <1% in all sam-
ples. Packaging efficiency was determined by calculating the
ratio of the total amount of each RNA present in the super-
natant by the amount present in the cells.
Analysis of in cell MIME data
Relation between nucleotide frequencies and the effect on
intracellular gRNA production. Employing the derivation
outlined in the Supplementary Text Equations (S1)–(S12),
we can deduce the effect of a mutation m at position i in
the RNA from the frequency of that mutation in the DNA
library relative to the frequency in the cells c, i.e.
Kmprod (i ) =
kwprod · δmu
kmprod · δwu
(i ) ≈ S
m
DNA
SwDNA
· S
w
c (t)
Smc (t)
(i ) , (1)
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where kwprod(i ), k
m
prod(i ) denote the rate of intracellular pro-
duction of the wild type viral RNA and the viral RNA that
carries a particular mutation (i.e. A→C, A→G, A→U, if
the wild type base is adenosine) at position i and δwu , δ
m
u
are the corresponding rates of RNA degradation. The ra-
tios S
m
DNA
SwDNA
(i ) and S
w
c (t)
Smc (t)
(i ) denote the frequency of mutations
in the DNA library and in the pool of viral RNA located
in the cell. Whenever the measure above is larger than 1,
mutations decrease HIV-1 RNA levels. In order to identify
regions that are important for gRNA production, one may
also depict the impact of the mutation mmax(i) that has a
maximal impact at position i only, as shown in Figure 2A;
where mmax (i ) = argmax
m
|log2(Kmprod(i ))| and where m de-
notes all those mutations that have a significant impact on
binding at nucleotide position i (if any), or all possible mu-
tations otherwise.
Relation between nucleotide frequencies and the effect on
packaging. Similarly, using derivations (S1–S6) and (S13–
S19) in the Supplementary Text, we can deduce the effect
of any mutation m at position i in the RNA on packaging
from the frequency of mutationm in the cell c relative to the
frequency in the virions v, i.e.
Kmpack (i ) =
kwon
kwof f + krel
·
kmof f + krel
kmon
(i ) ≈ S
m
c (t)
Swc (t)
· S
w
v (t)
Smv (t)
(i ) , (2)
where kwon , k
m
on, k
w
of f , k
m
of f denote the binding- and dissocia-
tion rate of the RNA to/from the packaging complex and
the rate krel denotes the rate at which RNA bound to the
packaging complex is released from the cell after packing
into nascent virions. In order to identify regions that are
important for packaging, one may also depict the impact of
the mutationmmax(i) that has a maximal impact at position
i only, as shown in Figure 3A.
Error correction. Themutation frequencies Sm/Sw needed
to evaluate Equations (1) and (2) are not known exactly,
however, next generation sequencing (NGS) of the distinct
RNA pools (DNA library, cellular RNA and RNA in viri-
ons) gives their frequencies in theNGS reads Rm/Rw. These
reads however contain substantial sequencing errors, which
we have to correct for, akin to the method presented in the
Supplementary Notes of (31,39). Error correction allows us
then to directly estimate the effects of each mutation m for
all position i from the nucleotide frequencies observed in
theNGS reads, provided we have a sufficient signal-to-noise
ratio (see Supplementary Text):
Kmprod (i ) ≈
RmDNA
RwDNA
− κw→mDNA
Rmc
Rwc
− κw→mc
(i ) , (3)
where κw→m(i ) denotes the probability to falsely detect a
wild type nucleotide w as some mutant m at position i.
κw→m(i ) is computed from experiments with wild type li-
braries for each type of mutation m and for each position
i, akin to (31,39) and as exemplified in the Supplementary
Text.
Similarly, for packaging, we derive
Kmpack (i ) ≈
Rmc
Rwc
− κw→mc
Rmv
Rwv
− κw→mv
(i ) , (4)
Statistical assessment of effects. The above described
method provides a single estimate of the relative effect for
each nucleotide position and for each possiblemutation, but
it does not assess the confidence range of this estimate, or
whether a mutation at position i has a significant impact on
binding. In the following, we make use of a jacknife-like re-
sampling procedure to estimate the confidence of each rel-
ative effect estimate, analogous to the methods in (31,39):
In brief, if we are interested in the effect of a mutation m at
position i, then for each pair of nucleotide positions (i,j), we
can re-compute Km,wprod(i, j ), respectively K
m,w
pack(i, j ), N times
(i.e. for each j = i). Each of these estimates can be computed
according to:
Km,wprod (i, j ) ≈
Rm,wDNA
Rw,wDNA
− κw→m,wDNA
Rm,wc
Rw,wc
− κw→m,wc
(i, j ) , (5)
and analogously,
Km,wpack (i, j ) ≈
Rm,wc
Rw,wc
− κw→m,wc
Rm,wv
Rw,wv
− κw→m,wv
(i, j ) , (6)
where κw→m,w(i, j ) denotes the probability to falsely de-
tect a wild type nucleotide w at position i as some mu-
tant m and to correctly detect the wild type at position j
= i as wild type, with derivations provided in the Supple-
mentary Text. To test whether a mutation at position i sig-
nificantly increases/decreases gRNA production, i.e. H0 :
log2(Kmprod(i )) ≤ c, H1 : log2(Kmprod(i )) > c, the raw P-value
can be computed according to
Pm− (i ) =
#log2
(
Km,wprod (i, j )
)
≤ c
#Km,wprod (i, ∗)
, (7)
where ‘#’ denotes the ‘number of estimates’ and * indicates
that all positions j are evaluated. To test whether a mutation
at position i significantly decreases Kprod,
Pm+ (i ) =
#log2
(
Km,wprod (i, j )
)
≥ −c
#Km,wprod (i, ∗)
(8)
We used P < 0.05 to detect significance. Note,
that one can test any threshold c ≥ 0 (e.g. 2-fold
increase/decrease, etc.). Throughout the manuscript
we chose c = |N−1∑i log2(˜Kmprod(ı))| i.e. the average over
all positions i, i.e. c = 0.42. An analogous scheme can
be used to assess the effects on packaging, where we
determined threshold c = 0.41. All reported P-values
were corrected by the false discovery rate (FDR)-based
method of Benjamini-Hochberg.
Quality criteria. For each pair of readsRm,w(i,j) /Rw,w(i,j),
we assessed its respective signal-to-noise ratio in the corre-
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Figure 2. In cell Mutational Interference Mapping Experiment (in cell MIME) discovery of RNA motifs regulating HIV-1 gRNA production (A) Log2
Kprod showing the maximal effect of mutations on RNA production in cells with the HIV-1 5′ UTR and Gag coding region (smoothed with a linear,
two-sided convolution filter of width 2). Functional domains are indicated with coloured boxes below the graph. Positions with significant effects on RNA
production are indicated by black triangles above the graph. Three regions with significant (P < 0.05) and strong (log2 Kprod ≥ 1 or ≤ –1; gray dotted line)
effects on gRNA production are highlighted with red circles. (B to D) Mutations with maximal effect on log2 Kprod mapped on RNA structure. Positions
impairing RNA production are shown in red. Positions improving RNA production shown in blue. Box and whisker plots show effect of each class of
mutation on log2 Kprod. Black dot shows median, box shows quartiles (25% and 75%) and whiskers show extremes (excluding outliers beyond 1.5× IQR).
Mutation classes are colour coded: red mutated to A; green mutated to C; blue mutated to G; yellow mutated to U. (B) Effect of mutations on gRNA
production (log2 Kprod) mapped to TAR. (C) Effect of mutations on gRNA production (log2 Kprod) mapped to 5′ PolyA. All mutations to AAUAAA
sequence improve gRNA production except for a single A to U mutation. (D) Effect of mutations on gRNA production (log2 Kprod) mapped to SL2.
Mutations impairing gRNA production cluster to the U1 snRNA binding site.
sponding RNA pool (DNA, cell and virion) according to:
Dm,w (i, j ) ≈ R
m,w (i, j )
Rw,w (i, j ) · κw→m,w (i, j ) . (9)
If the ratio was below the user-supplied threshold of 2
in both samples (DNA library versus cell and cell versus
virion), the corresponding estimates in Equations (5) and
(6) were discarded. If the signal was below the threshold in
only one of the samples, the respective estimate was tagged
as either being a lower- or upper estimate of the mutations’
effect and assigned the value of the median effect estimate
on RNA production or packaging respectively. This has
the following reason: if a mutation strongly decreases RNA
production, the frequency of that mutation in the cellular
RNA may fall below the required signal-to-noise ratio (a
multiple of the sequencing error) and the (negative) effect
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Figure 3. In cell Mutational Interference Mapping Experiment (in cell MIME) discovery of RNA motifs regulating HIV-1 gRNA packaging. (A) Log2
Kpack showing the maximal effect of mutations on RNA packaging with the HIV-1 5′ UTR and Gag coding region (smoothed with a linear, two-sided
convolution filter of width 2). Functional domains are indicated with coloured boxes. Positions with significant effects on gRNA packaging are indicated
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on RNA production may actually be higher than estimable.
Conversely, if the frequency of that mutation was below
the minimum signal-to-noise ratio in the DNA library, but
HIV-1 RNA levels increase in the cellular RNA above the
threshold, the (positive) effect on RNA production may
actually be higher than estimable. Likewise, if a mutation
strongly decreases packaging, the frequency of that muta-
tion in the virions may also fall below the sequencing error,
while the signal within the cells is sufficient. Again, the ac-
tual (negative) effect on packaging may be larger than es-
timable. We only evaluated Equations (5) and (6) for posi-
tions jwhere the total number of sequence fragments cover-
ing both i and j was at least 50% of the maximum coverage.
For determiningP-values, at least 300 estimates had to fulfil
the quality criteria.
RESULTS
Mutational interference mapping experiment (MIME) in
cells
The 5′UTR folds into a series of functional domains that
regulate almost every stage of the HIV-1 life cycle (2,3,5),
including intracellular gRNA production and packaging
into viral particles. For the most part, the RNA sequences
regulating these processes have been mapped to individual
stem loops, but a complete nucleotide level understanding
of their function is largely lacking. We recently developed
Mutational Interference Mapping Experiment (MIME) for
dissecting RNA structure and function at single nucleotide
resolution (31). This technique is based on (i) the random
mutation of the RNA of interest (ii) the physical separa-
tion of RNA into functional and non-functional popula-
tions and (iii) high-throughput sequencing to identify mu-
tations affecting function. In theory, MIME can be applied
to any process where functional and non-functional RNAs
can be physically separated, including within cells during
a native viral replication cycle. We reasoned that during
replication, mutated viral RNA would be naturally segre-
gated into functional and non-functional populations. That
is, correctly transcribed and processed viral RNAs will ac-
cumulate in the cytoplasm over RNAs that are poorly tran-
scribed or degraded due to defective processing. Similarly,
viral RNAs that are efficiently selected for packaging will
be more abundant in virions compared to packaging de-
fective RNAs. By physically isolating and sequencing these
mutant populations, regulatory RNA controlling two dif-
ferent stages of viral replication can be dissected in cells at
unprecedented detail.
The entire 5′UTR and the beginning of the Gag cod-
ing region (6,26,27) is thought to contain RNA sequences
regulating HIV-1 replication, therefore we targeted the first
∼500 nucleotides of the gRNA for functional analysis. Be-
cause mutating the Gag coding region could complicate the
identification of non-coding regulatory RNA i.e. by intro-
ducing mutations that interfere with viral assembly, we first
designed a conditional co-transfection system to separate
the production of mutated gRNA from the expression of
the viral structural proteins. gRNA was expressed from the
lab adapted pNL4.3HIV-1 vector modified to include (i) re-
striction sites for cloning of the mutant library, (ii) a substi-
tution in the gagATG start codon preventing Gag/Gag-Pol
expression, (iii) a stop codon preventing Tat expression and
(iv) a deletion in env for biosafety purposes. Unaltered viral
proteins Pr55Gag, Pr160GagPol and the accessory proteins Tat
and Rev were expressed from a separate packaging vector.
In this experimental setup, only co-transfected cells produce
gRNA, ensuring that all gRNA is produced in the presence
of the viral assembly machinery. The inclusion of restric-
tion sites did not affect viral replication in single round as-
says (Supplementary Figure S1), and the ATG start codon
mutation prevents Gag expression without significantly af-
fecting encapsidation (27).
We performed in cell MIME (Figure 1B) using six mu-
tant libraries tested in three independent experiments (two
mutant libraries per experiment). Mutations were intro-
duced using commercial PCR based mutagenesis technol-
ogy. These libraries were then cloned into the gRNA ex-
pression vector and co-transfected into 293T cells together
with the packaging vector. Viral and cellular gRNA were
harvested, reverse transcribed, randomly fragmented, and
sequenced using the Illumina HiSeq 2500 platform in 100
nt paired end mode. We also sequenced DNA derived from
both thewild-type andmutantDNA libraries, with the non-
mutated WT sequences used to control for errors intro-
duced during library preparation and sequencing.
Altogether, we aligned 180 million sequences to the ref-
erence genome, finding 1.08 × 108 mutations from 2.15 ×
1010 base pairs (Supplementary Table S2). Raw substitu-
tion rates were found to be significantly higher in the mu-
tant library compared to the WT controls (Supplementary
Figure S2), demonstrating that biologically relevant muta-
tions could be clearly distinguished from the background
errors introduced during library preparation and sequenc-
ing (P-value < 0.01). Importantly, we were able to use the
substitution frequencies in the wild-type control to obtain
error-corrected mutation frequencies, thus eliminating any
biases from errors introduced during library preparation
and sequencing (Materials and Methods section and Sup-
plementary Text) (31,39). Error-corrected mutation rates
were similar across all six independent libraries from the
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
by black triangles. Two regions with significant (P < 0.05) and strong (log2 Kpack ≥ 1; gray dotted line) effects on gRNA packaging are highlighted with
dot red line/circle. (B andC) Mutations with maximal effect on log2 Kpack represented on RNA structure. Positions impairing gRNA packaging are shown
in red. Positions improving gRNA packaging are shown in blue. Box and whisker plots show effect of each class of mutation on log2 Kpack. Black dot
shows median, box shows quartiles and whiskers show extremes (excluding outliers beyond 1.5× IQR). Mutation classes are colour coded: red mutated
to A; green mutated to C; blue mutated to G; yellow mutated to U. (B) Effect of mutations on gRNA packaging expressed as Log2 Kpack mapped to 5’
PolyA. All mutations to AAUAAA sequence impair gRNA packaging except for a single A to U mutation. (C) Effect of mutations on gRNA packaging
expressed as log2 Kpack mapped to RNA structure in the region SL1–SL3. (D) Qualitative comparison between the significant effects of mutations on
Pr55Gag binding determined by in vitro MIME (upper portion, green) and the effects of mutations on gRNA packaging by in cell MIME (lower portion,
blue). Sites significantly affecting both are pictured red. Color-coded arrows below (for in cell) and above (for in vitro) indicate the affected functional
domain (colored boxes on the bottom). Filled arrows show significant effects at sites in both in vitro and in cell.
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three independent experiments (Supplementary Figure S3)
and were highly reproducible for all classes of mutations
(Supplementary Figures S4 and S5). Importantly, error cor-
rected mutation rates steadily decreased from DNA (me-
dian = 4.8 × 10−3), cellular gRNA (median = 4.2 × 10−3)
to virion gRNA (median = 3.3 × 10−3) providing evidence
for purifying selection as the viral life-cycle proceeds (Sup-
plementary Figure S3). Interestingly, A–G mutations were
found to be consistently more abundant in cellular gRNA
(Supplementary Figure S6) compared to the inputDNA (P-
value < 0.01). These cellular A–G mutations were enriched
at 5′AA3′ and 5′UA3′ dinucleotides and seemed to cluster
at unpaired adenines near regions of double stranded RNA
structure (Supplementary Figure S7). Although the biolog-
ical basis for these abundant A-Gmutations is unclear, their
nature is suggestive of an editing activity by the dsRNA
adenosine deaminases, ADAR1 or ADAR2 (40,41) (Sup-
plementary Figure S7). Whilst intriguing, this phenomenon
is likely unrelated to the processes of gRNA production and
packaging investigated here, so we ignored this class of mu-
tation in the following analysis.
Regulation of intracellular gRNA production
We first focused on identifying RNA sequences regulating
gRNA production in infected cells by comparing the muta-
tion rate in the DNA library with mutations found in the
gRNA in cells. Intuitively, mutations impairing gRNA pro-
duction should be depleted in cells compared to the input
DNA. Conversely, mutations improving RNA production
should be enriched in the cellular gRNA compared to the
input DNA library. Indeed, formal modelling of this bio-
logical process revealed a direct relation between mutation
frequency and effect on gRNA production (Supplementary
Text). In other words, the frequency of a mutation m at
position i in the DNA library SmDNA/S
w
DNA (i ), divided by
the mutation frequency in the cellular RNA Smc /S
w
c (i ) is di-
rectly proportional to the decrease/increase of intracellular
viral RNA production caused by that mutation. By adapt-
ing a previously developed analytical framework (31,39),
we were able to infer the mechanistic effects of all muta-
tions m at all positions i on gRNA production and stability
simultaneously, summarized as Kmprod(i ) (see Equation (1)
in Materials and Methods and Supplementary text). More-
over, we were also able to statistically ascertain mutation ef-
fects at each position. Kmprod(i ) > 1 means that the mutation
(m) at position (i ) decreases gRNA production and stabil-
ity. Conversely, Kmprod(i ) < 1 identifiesmutations (m) at posi-
tion (i ) that increase gRNA production and stability. Upon
performing this analysis, we found three distinct regulatory
regions that strongly and significantly affected gRNA pro-
duction, both positively and negatively (Figure 2A, Supple-
mentary Data Files). These regions mapped to the domains
TAR, PolyA and SL2, respectively.
Unsurprisingly, TAR was identified as a positive regu-
lator of gRNA production, consistent with its crucial role
in enhancing viral transcription (42,43). This was seen as a
strong depletion of mutations in TAR in the cellular gRNA
when compared to the input DNA library (Figure 2A, 2B).
Although we were not able to analyse the extreme 5′ part of
the TAR (due to the binding of a specific primer to this re-
gion during sequencing library preparation), it was notable
that mutations to the apical portion were more strongly de-
pleted in cells compared to the distal portion of the stem-
loop (Figure 2B). This apical region is known to be impor-
tant for gRNA production by assembling with the HIV-1
Trans-Activator of Transcription (Tat) protein and the cel-
lular factor P-TEFb (42–47). Furthermore, these results are
in agreement with detailed mutant-revertant and phyloge-
netic studies showing that the distal portion of TAR is less
important for gene expression compared to the apical por-
tion (48,49). Altogether, these data evidence the ability of
in cell MIME to discover regulatory RNA in an unbiased
fashion.
The second regulatory motif was found to reside within
the 5′ PolyA. Unexpectedly, mutations in the 5′ PolyA were
enriched in cells compared to the input DNA, indicating
that this motif plays a negative role in gRNA production.
Strikingly, mutations improving gRNAproductionmapped
precisely to the 73AAUAAA78 hexamer within the 5′ PolyA
apical loop (Figure 2A, 2C). All mutations to this hexamer
were enriched in cellular gRNA compared to DNA, except
for a single 73AAUAAA78 to 73AUUAAA78 substitution
(Figure 2C). As AAUAAA and AUUAAA are the most
abundant cellular polyadenylation signals (50), these data
imply a role for the cellular polyadenylation machinery in
regulating intracellular gRNA levels.
The third regulatory motif mapped to the splice donor
site within SL2. Here, mutations were strongly depleted in
cellular gRNA compared to DNA (Figure 2A, D) demon-
strating that sequences within SL2 are required for gRNA
production. Interestingly, mutations disrupting gRNA pro-
duction mapped precisely to the U1snRNA binding site
289GGUGAGU295 (Figure 2D), and all classes of mutation
to this region disrupted gRNA production. This was some-
what surprising, as one might expect that disrupting the
splice donor site would increase unspliced gRNA produc-
tion by eliminating the splicing of viral RNAs.Nevertheless,
the opposite effect is observed here, and our data argue that
an interaction between U1snRNA and the splice donor site
is required for gRNA production.
Regulation of gRNA packaging
We next searched for RNA motifs regulating gRNA pack-
aging into virions by comparing the mutation rate in the
cellular RNA with that found in RNA extracted from vi-
ral particles. In cells, gRNA packaging comprises multi-
ple molecular events, including the formation of a pro-
tein : RNA packaging complex, its transport to the cell
surface, and its assembly into viral particles. Modelling of
this process demonstrates that the frequency of a muta-
tion m at position i in the cells Smc /S
w
c (i ) divided by the
mutation frequency in the virion RNA Smv /S
w
v (i ) is pro-
portional to the mutation’s effect on packaging (see Equa-
tion (2) in Methods and Supplementary Text). We derived
the term Kmpack(i ) that summarizes the underlying processes
(Equation 2). When Kmpack(i ) > 1, the mutation m at po-
sition i decreases gRNA packaging, when Kmpack(i ) < 1, it
increases packaging. Analogous to the analysis of in cell
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MIME data for RNA production, we adopted the previ-
ously developed analytical framework for error correction
and statistical analysis (31,39) (Materials andMethods sec-
tion and Supplementary Text). Upon analysis, we identified
two distinct regions that strongly and significantly affected
gRNA packaging (Figure 3 A, Supplementary Data Files).
These regulatory sequences mapped to the 5′ PolyA and the
region SL1-SL3, respectively.
Strikingly, the packaging signal within 5′ PolyA mapped
precisely to the same 5′ PolyA sequence 73AAUAAA78
that we identified as a strong regulator of gRNA produc-
tion (Figure 3A and 3B). Indeed, mutations to this se-
quence have similar effects on gRNA packaging as mu-
tations to the Psi region (Figure 3A). Like their effect
on gRNA production, all mutations to this hexamer se-
quence impaired gRNA packaging into virions, except for
a single 73AAUAAA78 to 73AUUAAA78 substitution (Fig-
ure 3B). Again, because 73AAUAAA78 and 73AUUAAA78
sequences function as canonical polyadenylation signals,
our data provide evidence that the cellular polyadenylation
machinery plays an important role in regulating not only
gRNA production, but also its incorporation into viral par-
ticles (50).
The second packaging signal overlapped the domains
SL1 to SL3 (Figure 3C) that we have previously identi-
fied as the Pr55Gag binding site in vitro (31). These data
therefore confirm the idea that Pr55Gag is a central player
in the selection of the gRNA (Figure 3D). However, we
did find some differences between the sequences required
for Pr55Gag binding in vitro and those directing gRNA
packaging into virions. First, and most remarkably, the
257GCGCGC262 palindromic sequence within the SL1 api-
cal loop seen as crucial for Pr55Gag binding to gRNA in
vitro, was not required for gRNA packaging in cells (Fig-
ure 3C and 3D, Supplementary Figure S8). Second, SL2
was slightly more important for gRNA packaging in cells
compared to Pr55Gag binding in vitro. However, it remained
relatively minor when compared to SL1 and SL3 (Figure
3D). Finally, mutations to the stem of SL1 had compara-
ble effects on packaging in cells as mutations to the stem of
SL3, in contrast to the situation in vitrowhere SL1 stemmu-
tations were much more deleterious than mutations to the
SL3 stem (Supplementary Figure S8) (4,31). Altogether, the
region SL1-SL3 is a major gRNA packaging determinant,
with SL1 shown to be the most important stem-loop given
that is over 2.5 times larger than SL3 (2,3).
Role of the AAUAAA PolyA motif in gRNA production and
packaging
To confirm the role of the 5′ PolyA and theU1snRNAbind-
ing site on gRNA production, we introduced mutants into
these two regions and tested their impact on viral repli-
cation in transfected cells by reverse transcription quanti-
tative PCR (RT-qPCR). We inhibited the 5′ polyadenyla-
tion signal either by its complete deletion (73AAUAAA78)
or its mutation to 73AAUGAA78 (Figure 4A). We also in-
cluded a 73AUUAAA78 mutation to serve as a canonical
polyadenylation control (Figure 4A). Whilst disruption of
5′ polyadenylation did not lead to a detectible increase
in the quantity of gRNA in the cell compared to wild-
type (99.0% 73AAUAAA78; 100.2% 73AAUGAA78), we
did observe a significant increase in the quantity of spliced
RNA produced in the 5′polyadenylation defective mutants
compared to wild-type (266.4% 73AAUAAA78 P<0.05;
292.8% 73AAUGAA78 P < 0.01) (Figure 4B). On the other
hand, the 73AUUAAA78 mutant produced both gRNA and
spliced RNA at levels comparable to wild-type (107.6%
gRNA; 131.7% spliced RNA) (Figure 4B). Together, these
data confirm that the 5′PolyA canonical polyadenylation
signal regulates gRNA production.
We next assessed the role of the 289GGUGAGU295
U1snRNA binding site by designing a mutation predicted
to disrupt 289UACGAGU295 U1snRNA binding (Figure
4A). Disruption of this binding site led to a thousand-fold
reduction in cellular levels of gRNAand splicedRNA (0.3%
genomic; 0.15% spliced) (Figure 4B) whereas combining the
U1snRNA binding site mutant 289UACGAGU295 with a
deletion of the 5′ PolyA 73AAUAAA78 signal caused lev-
els of gRNA to return to wild-type (110.9%). These data
demonstrate a functional interaction between the 5′PolyA
and the U1snRNA binding site in gRNA production in
agreement with a model that U1snRNA binding is required
to inhibit 5′ premature polyadenylation (51,52). To our sur-
prise, spliced viral RNA could also be detected at nearly
wild-type levels in this double mutant (118.3%) despite dis-
ruption of the U1snRNA binding site. Sequencing of the
PCR products revealed that splicing still occurred within
SL2, even in the absence of a canonical splice donor se-
quence, but the splice site was shifted by four nucleotides
in the 3′ direction (Supplementary Figure S9). Activation
of cryptic splice donor sites has been observed upon muta-
tion of the HIV-1 gRNA (52,53). This highlights that splice
site selection is extremely complex, and likely balanced by
RNA structure (54,55) as well as interactions between pos-
itive and negative splicing elements (53).
To further assess the role of the PolyA sequence on
gRNA packaging, we next quantified by RT-qPCR the
relative packaging efficiency of gRNA and spliced vi-
ral RNAs into viral particles expressed as the ratio of
RNA found in cells compared to virus (56). We found
a significant reduction (P<0.05) in packaging efficiency
to 43% and 48% of wild-type, for the 73AAUAAA78
and 73AAUGAA78 mutants respectively, whereas the pack-
aging efficiency of the 78AUUAAA78 mutant remained at
92% of wild-type (Figure 4C). Conversely, we found that
spliced viral RNA was incorporated with much greater effi-
ciency in the 73AAUAAA78 and 73AAUGAA78 mutant, at
266% and 293% of wild-type, respectively (Figure 4C). This
compared to a non-significant 131% of wild-type spliced
gRNA incorporation for the 73AUUAAA78 mutant (Fig-
ure 4C). Altogether our results demonstrate that a canon-
ical polyadenylation motif in the 5′ PolyA is required for
efficient gRNA packaging, even though it is ordinarily re-
pressed during HIV-1 replication.
DISCUSSION
RNA molecules are important regulators of biological ac-
tivity (1). They play key roles in bacterial (57) or viral infec-
tion processes (58,59), and defects in RNA regulation have
been implicated in human disease (60). Although thismakes
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Figure 4. Role of the AAUAAA polyA motif in gRNA production and packaging. (A) 5′PolyA mutants contain point mutations or deletions to the
AAUAAA sequence. SL2 mutant containing substitutions within the U1snRNA binding site. (B) Production of gRNA and spliced viral RNA (mRNA
Tat) for 5′ polyA and SL2 mutants. Bar charts represent six independent experiments. (C) Relative packaging efficiency of gRNA and spliced viral RNA
into viral particles, expressed as a virus/cellular RNA (36). Bar charts represent 3 independent experiments. Statistical tests were carried out using ANOVA
corrected for multiple comparisons.
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RNA an extremely attractive medical target, RNA-based
treatments have so far been challenging to develop.
The first step in exploiting RNA as a drug target is to
identify RNA motifs with the most potential for thera-
peutic intervention. Unfortunately, the functional flexibil-
ity of RNA means that the same stretches of RNA of-
ten perform multiple roles, which greatly complicates the
identification of regulatory RNA by traditional truncation
and deletionmutagenesis. This problem is especially evident
within RNA viral genomes, where fierce evolutionary pres-
sure for ‘data compression’ means that regulatory and cod-
ing regions overlap in complex ways that impede the un-
derstanding of their function. Here, we have implemented
in cell MIME to pinpoint regulatory RNA in an unbiased
fashion at single nucleotide resolution (31,39). Using differ-
ent methods of functional selection, we could dissect a com-
plex regulatory network controlling gRNA production and
packaging into virions (Figure 5). Surprisingly, a common
sequence within 5′ PolyA both negatively and positively reg-
ulated these respective processes.
With regards to gRNA production, we were able to iden-
tify three distinct RNAmotifs (Figure 2). Reassuringly, mu-
tations to TAR impaired gRNA production, with the api-
cal portion proving to be more important for gRNA pro-
duction than the distal portion. These results are in agree-
ment with the deletion and mutagenesis studies pointing
to the minimal sequences required for transactivation as
spanning residues 19 to 43 (61,62). Although we were not
able to analyse the U-rich bulge (nucleotides 23–25) con-
stituting the binding site for the viral Tat protein (63,64),
we could see the importance of the loop sequence (nu-
cleotides 29–34) serving as the binding site for P-TEFb
(65,66). Interestingly, TAR is assumed to be the most im-
portant motif for gRNA production, but we were able to
identify several point mutations that were more detrimen-
tal to viral RNA levels in cells than those mapping to TAR.
These mutations clustered within the U1 snRNA binding
site within SL2 suggesting a crucial role for the splicing
factor U1snRNA in gRNA production. Indeed, binding
of U1 snRNP, and in particular the U1 snRNP protein
70K, to the HIV-1 gRNA is important for the repression
of polyadenylation at the 5′ PolyA site (51,52,67). Without
this repression, only short prematurely polyadenylated tran-
scripts would be generated, preventing production of the
full-length gRNA. In agreement, our mutations designed
to impair U1 snRNA binding strongly repress gRNA pro-
duction, and that this phenotype could be counteracted by
deletion of the 73AAUAAA78 (Figure 4). We also observed
that individual mutants to 73AAUAAA78 were enriched in
cells compared to the wild-type sequence. Presumably, dis-
ruption of the 5′ canonical polyadenylation signal enhances
viral RNA production by eliminating low levels of prema-
ture cleavage and polyadenylation. The general assumption
is that 5′ PolyA is efficiently repressed in wild-type HIV-
1 through inhibitory RNA structure (68–71), proximity to
the 5′ cap (72,73), the presence of downstream inhibitory
sequences (51,52), and the absence of upstream activating
sequences that are only present at the 3′ end of the gRNA
(72,73). Our data argue that some level of cleavage and
polyadenylation still occurs within the wild-type 5′ PolyA
despite these inhibitory mechanisms (71).
With regards to gRNA packaging, we identified two dis-
tinct regions required for incorporation of gRNA into viral
particles (Figure 3). The central packaging signal spanned
SL1 to SL3 and closely corresponds to the Pr55Gag binding
site previously defined in vitro (4,31) and a region found to
bind Pr55Gag in PAR-CLIP crosslinking experiments in cells
(32). Mutations to the 257GCGCGC262 sequence within
the apical loop of SL1 did not impair gRNA packaging
in cells. This palindromic sequence initiates gRNA dimer-
ization via a kissing loop interaction – a conserved phe-
nomenon within the retroviridae family (10,74,75). gRNA
dimerization is required for viral replication (19,20,76–78)
and presumed to be mechanistically linked to gRNA pack-
aging (20,21,79). Given that identical mutations severely
compromised Pr55Gag binding in a similar MIME assay
conducted in vitro (31), it was surprising to see that mu-
tations to this sequence did not impair gRNA packaging.
Nevertheless, our in cell data is consistent with modest ef-
fects on gRNA packaging seen with SL1 apical loop mu-
tants in a variety of studies (19,21,76,80,81). For example,
in one study a single G to U mutation 257GCGCUC262 lead
to a roughly two fold reduction in gRNA packaging (82),
whereas our in cell MIME data shows that this same mu-
tation packages 76% of wild-type (68–86% are the 5 and 95
percent confidence intervals) (Supplementary Data Files).
SL1 apical loop mutants may also have less impact in cells
compared to Pr55Gag binding assays conducted in vitro (76)
due to the presence of yet unidentified redundant dimeriza-
tion sites within the full length HIV-1 genome that were not
present on the short RNA fragment tested in vitro. Alterna-
tively, primary T-lymphocytes can partially rescue defects
in reverse transcription induced by deletion or mutation of
SL1, implying that cellular factors can also compensate for
SL1 defects (76). Regardless of the role of the SL1 apical
loop sequence, the SL1 stem and internal loop itself is a
bona fide packaging signal, consistent with the fact that its
deletion leads to severe packaging defects (18,56,80).
Finally, we make the discovery that 73AAUAAA78 within
the 5′PolyA is an exceptionally strong packaging signal in
cells. Previous studies have shown that destabilizing the
PolyA hairpin decreases gRNA packaging (83,84) and that
complete deletion of PolyA reduces gRNA packaging by
70% (18,84), similar to a combined deletion of SL1 and
SL3 (56). Until now, the best explanation for why PolyA
acts as a packaging determinant is that it binds to Pr55Gag
directly during viral assembly (56). Although a truncated
version of the Gag protein bound 5′ PolyA in an in vitro
footprinting assay (85), this binding site was not seen by
in vitro MIME using full length Pr55Gag protein (31). Fur-
thermore, PAR-CLIP experiments conducted in cells also
did not identify 5′ PolyA as a Pr55Gag binding site (32).
We therefore find a mechanism involving the direct bind-
ing of Pr55Gag to the 5′ PolyA unlikely. Instead, our data
suggests that the cellular polyadenylation machinery and
gRNA packaging are mechanistically linked. Our evidence
is two-fold: first, we localized the 5′ PolyA packaging sig-
nal, at single nucleotide resolution, to the 73AAUAAA78
canonical polyadenylation signal; second, we showed that
all mutations to this sequence impair gRNA packaging ex-
cept for a single A to U mutation (73AUUAAA78) form-
ing the second most frequent polyadenylation signal found
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Figure 5. Five regulatory elements controlling HIV-1 replication. gRNA production is positively regulated by sequences within TAR and by the U1snRNP
binding site within SL2. gRNA production is negatively regulated by the AAUAAAmotif in 5′ polyA. TheU1snRNP binding site is required for repression
of 5′ polyadenylation. gRNA packaging into virions requires both the Pr55Gag binding site (SL1-SL3), and the AAUAAA motif in 5′ PolyA. Positive
regulatory elements are highlighted in green. Negative regulatory elements are highlighted in red.
in mammalian cells (86). Together, these facts argue that
a functional polyadenylation signal is required for gRNA
packaging into virions. This would explain why HIV-1 con-
serves the 5′ polyadenylation signal, even though its pres-
ence is detrimental for gRNA production. Other retro-
viruses, such asmousemammary tumor virus (MMTV) and
avian leukosis-sarcoma virus (ALSV), encode a single copy
of the AAUAAA polyadenylation signal in the 3′ end of the
gRNA, demonstrating that different (seemingly more logi-
cal) gRNA organisations are possible.
How might polyadenylation facilitate gRNA packaging?
Given that the gRNA packaging is thought to be mainly
determined by Pr55Gag, one simple explanation could be
that there exists a direct or indirect interaction between
Pr55Gag and the cellular polyadenylation machinery. This
interaction could help recruit or stabilize Pr55Gag on the
gRNA to ensure that viral assembly occurs preferentially
on the gRNA, rather than cellular RNAs. Interestingly, cel-
lular RNAs that are preferentially packaged into viral par-
ticles exhibit particularly long 3′UTRs (87), possibly be-
cause these mRNAs are more likely to contain inhibited up-
stream polyadenylation sequences than the equivalent cel-
lular RNAs with short UTRs. Which component(s) of the
polyadenylation machinery are involved in gRNA pack-
aging? The polyadenylation machinery comprises cleav-
age polyadenylation specificity factor (CPSF), cleavage fac-
tors Im and IIm (CFIm and CFIIm), cleavage stimula-
tory factor (CstF), poly(A) polymerase (PAP), and poly(A)
binding protein II (88). At least some of these cellular
polyadenylation factors bind to the 5′ polyadenylation sig-
nal even when cleavage and polyadenylation is repressed
(51,52,68). Amongst these factors, CPSF6––a subunit of
CFIm––stands out. Although it does not directly recognize
the AAUAAA sequence (88,89), it is a key player in mRNA
3′ end processing and is involved in the repression of 5′ prox-
imal polyadenylation sites (90,91). It also interacts with the
CA domain of Pr55Gag providing a possible link between
polyadenylation and HIV-1 biology (92–96). Delineating
the mechanistic contributions of the cellular polyadenyla-
tion machinery to gRNA packaging could provide a new
window of therapeutic opportunity not currently exploited
by antiretroviral therapy. However, further work will be re-
quired to define its potential role in HIV-1 gRNA packag-
ing.
In summary, we have used in cell MIME to identify at
single nucleotide resolution RNA motifs regulating gRNA
production and packaging into HIV-1 virions. One of the
major advantages of the in cell MIME method is that low
level random mutagenesis can pinpoint functional RNA
motifs whilst reducing the risk of RNA misfolding that of-
ten occurs when large and imprecise deletion mutants are
used. Although we have not done so here, in principle, in
cell MIME data can also be used to identify RNA sec-
ondary structure important for regulatory function through
the identification of compatible co-varying nucleotide posi-
tions. Thus, in cellMIME is a flexible and powerfulmethod-
ology should help to identify novel regulatory RNA motifs
in a wide range of pathogens, as well as lead to a better un-
derstanding of non-coding RNA molecules in eukaryotic
cells.
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